利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

115 条记录 (耗时 0.041 秒)

    KOC1-DERIVED PEPTIDE AND VACCINE INCLUDING SAME
    5.
    发明公开
    KOC1-DERIVED PEPTIDE AND VACCINE INCLUDING SAME 审中-公开

    公开(公告)号：EP3981416A3

    公开(公告)日：2022-07-06

    申请号：EP21202045.7

    申请日：2015-07-31

    申请人： OncoTherapy Science, Inc.

    发明人： TSUNODA, Takuya ,  OSAWA, Ryuji ,  YAMASHITA, Sachiko ,  WATANABE, Tomohisa ,  HIKICHI, Tetsuro

    IPC分类号： A61K35/12 ,  A61K35/14 ,  A61K39/00 ,  A61K48/00 ,  C07K7/06 ,  C07K7/08 ,  C07K16/18 ,  C12N5/10 ,  C12N15/09

    摘要： The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

    TOPK PEPTIDES AND VACCINES INCLUDING THE SAME
    7.
    发明公开
    TOPK PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
    TOPK多肽和疫苗包括相同

    公开(公告)号：EP3296317A1

    公开(公告)日：2018-03-21

    申请号：EP17198358.8

    申请日：2012-10-25

    申请人： OncoTherapy Science, Inc.

    发明人： NAKAMURA, Yusuke ,  OSAWA, Ryuji ,  WATANABE, Tomohisa ,  NAKAYAMA, Gaku ,  TSUNODA, Takuya ,  YOSHIMURA, Sachiko

    IPC分类号： C07K7/06 ,  A61K38/00 ,  A61K48/00 ,  A61P35/00 ,  C07K16/18 ,  C12N5/10 ,  C12N15/09 ,  G01N33/574 ,  A61K39/00 ,  C07K14/47 ,  C07K16/40 ,  C12N9/12 ,  G01N33/50

    摘要： As discussed in greater detail herein, isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of cancers and tumors, including, for example, acute myeloid leukemia (AML), bladder cancer, breast cancer, cervical cancer, cholan-giocellular carcinoma, colorectal cancer, diffuse-type gastric cancer, non small cell lung cancer (NSCLC), lymphoma, osteosarcoma, prostate cancer, renal carcinoma, small cell lung cancer (SCLC) and soft tissue tumor.

    摘要翻译： 如本文更详细讨论的，来自TOPK的分离的表位肽及其免疫原性片段具有诱导细胞毒性T淋巴细胞（CTL）的能力，因此适用于癌症免疫治疗，更具体地用作癌症疫苗。 本发明的肽包括包含TOPK衍生的氨基酸序列的肽及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，条件是这些修饰形式具有CTL 诱导性。 还提供了编码任何上述肽的多核苷酸以及包含任何上述肽或多核苷酸的药物组合物。 本发明的肽，多核苷酸和药物组合物在治疗和预防癌症和肿瘤（包括例如急性骨髓性白血病（AML），膀胱癌，乳腺癌，宫颈癌，胆管癌 结肠直肠癌，弥漫型胃癌，非小细胞肺癌（NSCLC），淋巴瘤，骨肉瘤，前列腺癌，肾癌，小细胞肺癌（SCLC）和软组织肿瘤。

    HJURP PEPTIDES AND VACCINES INCLUDING THE SAME
    9.
    发明授权
    HJURP PEPTIDES AND VACCINES INCLUDING THE SAME 有权
    HJURP肽和疫苗包括相同

    公开(公告)号：EP2545171B1

    公开(公告)日：2017-12-20

    申请号：EP11753055.0

    申请日：2011-03-10

    申请人： OncoTherapy Science, Inc.

    发明人： NAKAMURA, Yusuke ,  TSUNODA, Takuya ,  OHSAWA, Ryuji ,  YOSHIMURA, Sachiko ,  WATANABE, Tomohisa

    IPC分类号： C12N15/09 ,  A61K35/00 ,  A61K38/00 ,  C07K7/06 ,  C07K16/18 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/00 ,  C12N5/10

    CPC分类号： C07K14/4748 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00 ,  C07K7/06 ,  C07K16/18

    摘要： Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.